<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973475</url>
  </required_header>
  <id_info>
    <org_study_id>FUGES-023</org_study_id>
    <nct_id>NCT04973475</nct_id>
  </id_info>
  <brief_title>Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer</brief_title>
  <official_title>Prospective Clinical Trials on Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy With Lymph Node Dissection for Early Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the value of indocyanine green (ICG) in laparoscopic distal&#xD;
      gastrectomy with lymph node dissection for early gastric cancer.The patients with early&#xD;
      gastric adenocarcinoma (cT1, N-/+, M0) will be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written&#xD;
      informed consent will receiving injection of indocyanine greenat 8 points around the primary&#xD;
      tumor with gastroscope 1 day before surgery. During the operation, laparoscopic gastrectomy&#xD;
      and perigastric lymph node dissection were performed under ICG imaging equipment. After the&#xD;
      surgical specimens were isolated, under the fluorescent illumination of the ICG imaging&#xD;
      equipment, the lymph nodes that showed fluorescence and the lymph nodes that did not show&#xD;
      fluorescence were collected from each LN station.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>False negative rate</measure>
    <time_frame>One month after surgery</time_frame>
    <description>The number of positive lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>True positive rate</measure>
    <time_frame>One month after surgery</time_frame>
    <description>The number of positive lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>False positive rate</measure>
    <time_frame>One month after surgery</time_frame>
    <description>The number of negative lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>True negative rate</measure>
    <time_frame>One month after surgery</time_frame>
    <description>The number of negative lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of retrieved lymph nodes</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Total number of retrieved lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph node noncompliance rate</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Lymph node noncompliance was defined as the absence of lymph nodes that should have been excised from more than 1 lymph node station. Major lymph node noncompliance was defined as more than 2 intended lymph node stations that were not removed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Metastasis Lymph Nodes</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Number of Metastasis Lymph Nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis rate of lymph node</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Metastasis rate of lymph node</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity and mortality rates</measure>
    <time_frame>One month after surgery</time_frame>
    <description>This is for the early postoperative complication and mortality, which defined as the event observed within 30 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>3-year overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>3-year disease free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year recurrence pattern</measure>
    <time_frame>36 months</time_frame>
    <description>Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative morbidity rates</measure>
    <time_frame>1 day</time_frame>
    <description>The intraoperative postoperative morbidity rates are defined as the rates of event observed within operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first ambulation</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first ambulation in hours is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first flatus</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first flatus in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first liquid diet</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first liquid diet in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first soft diet</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first soft diet in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of postoperative hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of white blood cell count</measure>
    <time_frame>Preoperative 3 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of white blood cell count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of hemoglobin</measure>
    <time_frame>Preoperative 3 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of hemoglobin in gram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of C-reactive protein</measure>
    <time_frame>Preoperative 3 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The variation of C-reactive protein</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Early Gastric Cancer</condition>
  <condition>Indocyanine Green</condition>
  <condition>Lymph Node Dissection</condition>
  <arm_group>
    <arm_group_label>Experimental: Indocyanine Green Tracer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indocyanine Green Tracer will be used in laparoscopic distal gastrectomy with lymph node dissection for gastric adenocarcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine Green</intervention_name>
    <description>Laparoscopic distal gastrectomy with lymph node dissection for early gastric cancer using Indocyanine Green Tracer</description>
    <arm_group_label>Experimental: Indocyanine Green Tracer</arm_group_label>
    <other_name>ICG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 18 to 75 years&#xD;
&#xD;
          2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or&#xD;
             poorly differentiated) confirmed pathologically by endoscopic biopsy&#xD;
&#xD;
          3. Clinical stage tumor T1 (cT1), N0/+, M0 at preoperative evaluation according to the&#xD;
             American Joint Committee on Cancer (AJCC) Cancer Staging Manual Eighth Edition.&#xD;
             Preoperative staging was made by conducting mandatory computed tomography (CT) scans&#xD;
             and an optional endoscopic ultrasound&#xD;
&#xD;
          4. No distant metastasis, no direct invasion of pancreas, spleen or other organs nearby&#xD;
             in the preoperative examinations&#xD;
&#xD;
          5. Tumor located in the lower third of the stomach, expected to receive radical distal&#xD;
             gastrectomy&#xD;
&#xD;
          6. Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)&#xD;
&#xD;
          7. American Society of Anesthesiology score (ASA) class I, II, or III&#xD;
&#xD;
          8. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women during pregnancy or breast-feeding&#xD;
&#xD;
          2. Severe mental disorder&#xD;
&#xD;
          3. History of previous upper abdominal surgery (except laparoscopic cholecystectomy)&#xD;
&#xD;
          4. History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal&#xD;
             dissection&#xD;
&#xD;
          5. Enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging&#xD;
&#xD;
          6. History of other malignant disease within past five years&#xD;
&#xD;
          7. History of previous neoadjuvant chemotherapy or radiotherapy&#xD;
&#xD;
          8. History of unstable angina or myocardial infarction within past six months&#xD;
&#xD;
          9. History of cerebrovascular accident within past six months&#xD;
&#xD;
         10. History of continuous systematic administration of corticosteroids within one month&#xD;
&#xD;
         11. Requirement of simultaneous surgery for other disease&#xD;
&#xD;
         12. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by&#xD;
             gastric cancer&#xD;
&#xD;
         13. Forced expiratory volume in 1 second (FEV1)&lt;50% of predicted values&#xD;
&#xD;
         14. Rejection of laparoscopic resection&#xD;
&#xD;
         15. Preoperatively confirmed tumors invading the dentate line or duodenum&#xD;
&#xD;
         16. History of allergy to iodine agents&#xD;
&#xD;
         17. Tumor located in the upper third of the stomach, expected to receive radical total&#xD;
             gastrectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Ming Huang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fujian Medical University Union Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang-Ming Huang, MD</last_name>
    <phone>+86-13805069676</phone>
    <email>hcmlr2002@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zu-Kai Wang, MD</last_name>
    <phone>+86-15659036263</phone>
    <email>413966027@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastric Surgery</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chang-Ming Huang, Huang</last_name>
      <phone>Huang</phone>
      <email>hcmlr2002@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014 Aug;40(3):250-60. doi: 10.1111/apt.12814. Epub 2014 Jun 10. Review.</citation>
    <PMID>24912650</PMID>
  </reference>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Msika S, Chastang C, Houry S, Lacaine F, Huguier M. Lymph node involvement as the only prognostic factor in curative resected gastric carcinoma: a multivariate analysis. World J Surg. 1989 Jan-Feb;13(1):118-23; discussion 123.</citation>
    <PMID>2471364</PMID>
  </reference>
  <reference>
    <citation>Maruyama K, Gunvén P, Okabayashi K, Sasako M, Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg. 1989 Nov;210(5):596-602.</citation>
    <PMID>2818028</PMID>
  </reference>
  <reference>
    <citation>Zhang YX, Yang K. Significance of nodal dissection and nodal positivity in gastric cancer. Transl Gastroenterol Hepatol. 2020 Apr 5;5:17. doi: 10.21037/tgh.2019.09.13. eCollection 2020. Review.</citation>
    <PMID>32258521</PMID>
  </reference>
  <reference>
    <citation>Mocellin S. The Effect of Lymph Node Dissection on the Survival of Patients With Operable Gastric Carcinoma. JAMA Oncol. 2016 Oct 1;2(10):1363-1364. doi: 10.1001/jamaoncol.2016.2044. Review.</citation>
    <PMID>27442439</PMID>
  </reference>
  <reference>
    <citation>Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021 Jan;24(1):1-21. doi: 10.1007/s10120-020-01042-y. Epub 2020 Feb 14.</citation>
    <PMID>32060757</PMID>
  </reference>
  <reference>
    <citation>Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995 Mar;82(3):346-51.</citation>
    <PMID>7796005</PMID>
  </reference>
  <reference>
    <citation>Kurokawa Y, Takeuchi H, Doki Y, Mine S, Terashima M, Yasuda T, Yoshida K, Daiko H, Sakuramoto S, Yoshikawa T, Kunisaki C, Seto Y, Tamura S, Shimokawa T, Sano T, Kitagawa Y. Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study. Ann Surg. 2021 Jul 1;274(1):120-127. doi: 10.1097/SLA.0000000000003499.</citation>
    <PMID>31404008</PMID>
  </reference>
  <reference>
    <citation>Baiocchi GL, Giacopuzzi S, Reim D, Piessen G, Costa PMD, Reynolds JV, Meyer HJ, Morgagni P, Gockel I, Santos LL, Jensen LS, Murphy T, D'Ugo D, Rosati R, Fumagalli Romario U, Degiuli M, Kielan W, Mönig S, Kołodziejczyk P, Polkowski W, Pera M, Schneider PM, Wijnhoven B, de Steur WO, Gisbertz SS, Hartgrink H, van Sandick JW, Botticini M, Hölscher AH, Allum W, De Manzoni G. Incidence and Grading of Complications After Gastrectomy for Cancer Using the GASTRODATA Registry: A European Retrospective Observational Study. Ann Surg. 2020 Nov;272(5):807-813. doi: 10.1097/SLA.0000000000004341.</citation>
    <PMID>32925254</PMID>
  </reference>
  <reference>
    <citation>Han SU, Hur H, Lee HJ, Cho GS, Kim MC, Park YK, Kim W, Hyung WJ; Korean Laparoendoscopic Gastrointestinal Surgery Study (KLASS) Group. Surgeon Quality Control and Standardization of D2 Lymphadenectomy for Gastric Cancer: A Prospective Multicenter Observational Study (KLASS-02-QC). Ann Surg. 2021 Feb 1;273(2):315-324. doi: 10.1097/SLA.0000000000003883.</citation>
    <PMID>33064386</PMID>
  </reference>
  <reference>
    <citation>Liu M, Xing J, Xu K, Yuan P, Cui M, Zhang C, Yang H, Yao Z, Zhang N, Tan F, Su X. Application of Near-Infrared Fluorescence Imaging with Indocyanine Green in Totally Laparoscopic Distal Gastrectomy. J Gastric Cancer. 2020 Sep;20(3):290-299. doi: 10.5230/jgc.2020.20.e25. Epub 2020 Aug 31.</citation>
    <PMID>33024585</PMID>
  </reference>
  <reference>
    <citation>Roh CK, Choi S, Seo WJ, Cho M, Son T, Kim HI, Hyung WJ. Indocyanine green fluorescence lymphography during gastrectomy after initial endoscopic submucosal dissection for early gastric cancer. Br J Surg. 2020 May;107(6):712-719. doi: 10.1002/bjs.11438. Epub 2020 Feb 7.</citation>
    <PMID>32031248</PMID>
  </reference>
  <reference>
    <citation>Cianchi F, Indennitate G, Paoli B, Ortolani M, Lami G, Manetti N, Tarantino O, Messeri S, Foppa C, Badii B, Novelli L, Skalamera I, Nelli T, Coratti F, Perigli G, Staderini F. The Clinical Value of Fluorescent Lymphography with Indocyanine Green During Robotic Surgery for Gastric Cancer: a Matched Cohort Study. J Gastrointest Surg. 2020 Oct;24(10):2197-2203. doi: 10.1007/s11605-019-04382-y. Epub 2019 Sep 4.</citation>
    <PMID>31485904</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Chang-Ming Huang, Prof.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Indocyanine Green Tracer</keyword>
  <keyword>Laparoscopic Distal Gastrectomy</keyword>
  <keyword>Lymph Node Dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

